Incannex wins US patent for IHL-42X obstructive sleep apnea therapy

Incannex Healthcare

Incannex Healthcare

IXHL

0.00
  • Incannex won a U.S. patent covering the IHL-42X composition and methods to treat obstructive sleep apnea.
  • Baseline patent expiry set for July 9, 2040; patent term extension under review pending potential FDA approval.
  • Move strengthens exclusivity strategy for IHL-42X, an oral combination therapy with FDA Fast Track designation and positive Phase II data.
  • Company is preparing to start patient recruitment for the DReAMzz Phase 2 dose-optimization study.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Incannex Healthcare Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-071745), on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.